Merck Cozaar Nephropathy Label Should Include Cardioprotection Uncertainty
Executive Summary
Merck's Cozaar labeling for type 2 diabetic nephropathy should convey questions about cardioprotective effect and caution about substitution for ACE inhibitors, FDA's Cardiovascular & Renal Drugs Advisory Committee suggested at its April 12 meeting
You may also be interested in...
Accelerated Approval Great For “Me-Too” Products, FDA Says
CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.
FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution
An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C
Merck Cozaar Approval Nod For Nephropathy Gets Boost From Avapro Data
An advisory committee recommendation for Merck's Cozaar in the treatment of nephropathy in type 2 diabetes patients reflects supportive evidence from Bristol-Myers Squibb/Sanofi's Avapro data.